1so2
From Proteopedia
(New page: 200px<br /> <applet load="1so2" size="450" color="white" frame="true" align="right" spinBox="true" caption="1so2, resolution 2.40Å" /> '''CATALYTIC DOMAIN OF...) |
|||
| Line 1: | Line 1: | ||
| - | [[Image:1so2.gif|left|200px]]<br /> | + | [[Image:1so2.gif|left|200px]]<br /><applet load="1so2" size="350" color="white" frame="true" align="right" spinBox="true" |
| - | <applet load="1so2" size=" | + | |
caption="1so2, resolution 2.40Å" /> | caption="1so2, resolution 2.40Å" /> | ||
'''CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B In COMPLEX WITH A DIHYDROPYRIDAZINE INHIBITOR'''<br /> | '''CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B In COMPLEX WITH A DIHYDROPYRIDAZINE INHIBITOR'''<br /> | ||
==Overview== | ==Overview== | ||
| - | Phosphodiesterases (PDEs) are enzymes that modulate cyclic nucleotide | + | Phosphodiesterases (PDEs) are enzymes that modulate cyclic nucleotide signaling and as such are clinical targets for a range of disorders including congestive heart failure, erectile dysfunction, and inflammation. The PDE3 family comprises two highly homologous subtypes expressed in different tissues, and inhibitors of this family have been shown to increase lipolysis in adipocytes. A specific PDE3B (the lipocyte-localized subtype) inhibitor would be a very useful tool to evaluate the effects of PDE3 inhibition on lipolysis and metabolic rate and might become a novel tool for treatment of obesity. We report here the three-dimensional structures of the catalytic domain of human PDE3B in complex with a generic PDE inhibitor and a novel PDE3 selective inhibitor. These structures explain the dual cAMP/cGMP binding capabilities of PDE3, provide the molecular basis for inhibitor specificity, and can supply a valid platform for the design of improved compounds. |
==About this Structure== | ==About this Structure== | ||
| - | 1SO2 is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with MG, HG9 and 666 as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/3',5'-cyclic-nucleotide_phosphodiesterase 3',5'-cyclic-nucleotide phosphodiesterase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.1.4.17 3.1.4.17] Full crystallographic information is available from [http:// | + | 1SO2 is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=MG:'>MG</scene>, <scene name='pdbligand=HG9:'>HG9</scene> and <scene name='pdbligand=666:'>666</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/3',5'-cyclic-nucleotide_phosphodiesterase 3',5'-cyclic-nucleotide phosphodiesterase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.1.4.17 3.1.4.17] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1SO2 OCA]. |
==Reference== | ==Reference== | ||
| Line 15: | Line 14: | ||
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
[[Category: Single protein]] | [[Category: Single protein]] | ||
| - | [[Category: Becker, J | + | [[Category: Becker, J W.]] |
[[Category: Chung, C.]] | [[Category: Chung, C.]] | ||
| - | [[Category: Edmondson, S | + | [[Category: Edmondson, S D.]] |
[[Category: Mastracchio, A.]] | [[Category: Mastracchio, A.]] | ||
| - | [[Category: Parmee, E | + | [[Category: Parmee, E R.]] |
| - | [[Category: Patel, S | + | [[Category: Patel, S B.]] |
| - | [[Category: Ploeg, L | + | [[Category: Ploeg, L H.Van Der.]] |
[[Category: Scapin, G.]] | [[Category: Scapin, G.]] | ||
| - | [[Category: Singh, S | + | [[Category: Singh, S B.]] |
| - | [[Category: Tota, M | + | [[Category: Tota, M R.]] |
| - | [[Category: Varnerin, J | + | [[Category: Varnerin, J P.]] |
[[Category: 666]] | [[Category: 666]] | ||
[[Category: HG9]] | [[Category: HG9]] | ||
| Line 31: | Line 30: | ||
[[Category: pde3b phosphodiesterase]] | [[Category: pde3b phosphodiesterase]] | ||
| - | ''Page seeded by [http:// | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 15:03:28 2008'' |
Revision as of 13:03, 21 February 2008
|
CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B In COMPLEX WITH A DIHYDROPYRIDAZINE INHIBITOR
Overview
Phosphodiesterases (PDEs) are enzymes that modulate cyclic nucleotide signaling and as such are clinical targets for a range of disorders including congestive heart failure, erectile dysfunction, and inflammation. The PDE3 family comprises two highly homologous subtypes expressed in different tissues, and inhibitors of this family have been shown to increase lipolysis in adipocytes. A specific PDE3B (the lipocyte-localized subtype) inhibitor would be a very useful tool to evaluate the effects of PDE3 inhibition on lipolysis and metabolic rate and might become a novel tool for treatment of obesity. We report here the three-dimensional structures of the catalytic domain of human PDE3B in complex with a generic PDE inhibitor and a novel PDE3 selective inhibitor. These structures explain the dual cAMP/cGMP binding capabilities of PDE3, provide the molecular basis for inhibitor specificity, and can supply a valid platform for the design of improved compounds.
About this Structure
1SO2 is a Single protein structure of sequence from Homo sapiens with , and as ligands. Active as 3',5'-cyclic-nucleotide phosphodiesterase, with EC number 3.1.4.17 Full crystallographic information is available from OCA.
Reference
Crystal structure of human phosphodiesterase 3B: atomic basis for substrate and inhibitor specificity., Scapin G, Patel SB, Chung C, Varnerin JP, Edmondson SD, Mastracchio A, Parmee ER, Singh SB, Becker JW, Van der Ploeg LH, Tota MR, Biochemistry. 2004 May 25;43(20):6091-100. PMID:15147193
Page seeded by OCA on Thu Feb 21 15:03:28 2008
